Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bempedoic Acid in Pediatric Patients With Heterozygous Familial Hypercholesterolemia
NCT05694260Phase 2Completed
- Sponsor
- Esperion Therapeutics
- Start
- Jan 2023
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, open-label trial of bempedoic acid in heterozygous familial hypercholesterolemia (HeFH) (3 cohorts), sponsored by Esperion Therapeutics. Primary endpoints: Observed Trough Plasma Concentration of ETC-1002 Following 8 Weeks of Steady State Dosing of Bempedoic Acid, Model-based Steady State Area Under the Concentration-time Curve Over 24 Hours of ETC-1002 and 2 more. Started Jan 2023; status: completed.
02
Drugs
bempedoic acid
03
Conditions
heterozygous familial hypercholesterolemia (HeFH)
Beyond the preview
Go deeper on NCT05694260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05694260.